← all drugs
Mesalamine Capsule, Extended Release
being discontinued · Gastroenterology · Snapshot: 2026-10-09
- Manufacturers listed
- Takeda Pharmaceuticals USA Inc., Mylan Pharmaceuticals Inc., a Viatris Company
- Machine-readable
- JSON for this drug
Presentations (3)
| Presentation | Company | Availability | Updated |
|---|---|---|---|
| Pentasa, Capsule, Extended Release, 500 mg (NDC 54092-191-12) | Takeda Pharmaceuticals USA Inc. | unknown | 09/16/2026 |
| Pentasa, Capsule, Extended Release, 250 mg (NDC 54092-189-81) | Takeda Pharmaceuticals USA Inc. | unknown | 09/16/2026 |
| Mesalamine, Capsule, Extended Release, .375 g (NDC 0378-1375-78) | Mylan Pharmaceuticals Inc., a Viatris Company | unknown | 08/25/2026 |
History
Daily tracking of this drug began 2026-08-27.
- 2026-08-27 — Mesalamine Capsule, Extended Release appeared on the FDA shortage list (being discontinued)
Each daily snapshot is compared with the one before it; status changes, availability-wording revisions, and arrivals or removals are listed here. A change the FDA makes and reverses between two snapshots is not seen. Every daily record is kept in the public repository.
Not medical advice. ShortSupply republishes the FDA's drug-shortage data with history added. Talk to your pharmacist or prescriber about your situation — never change medication based on this site.